Single-payload ADCs have a documented resistance problem in solid tumors, and Acepodia is betting its entire platform thesis on that gap. The company dosed its first patient in a Phase 1 trial of ACE723 in unresectable or metastatic hepatocellular carcinoma, making it the first molecule from Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) platform to reach a patient. The trial is enrolling at a site in China, with IND clearances from the FDA and China’s NMPA both granted in September 2026, followed by Taiwan FDA approval in October 2026.
ACE723 targets GPC3, a protein frequently expressed in HCC, and delivers two cytotoxic payloads designed to kill tumor cells through distinct mechanisms. The dual-payload design directly addresses tumor heterogeneity: when cancer cells downregulate one target pathway to escape a single payload, a second mechanism is already in play. The Phase 1 dose-escalation study will assess safety, tolerability, pharmacokinetics, and early anti-tumor activity, with the primary goal of defining a recommended dose for later-stage development and potential expansion cohorts.
The unmet need in later-line HCC is real. HCC accounts for more than 70% of liver cancer cases globally, and while first-line options have expanded (the FDA approved nivolumab plus ipilimumab in April 2025 for unresectable or metastatic disease), patients who progress on immunotherapy combinations have limited effective options afterward. That second-line gap is where ACE723 would need to prove its case. Acepodia’s underlying conjugation chemistry traces back to bio-orthogonal click chemistry from Nobel laureate Carolyn Bertozzi’s laboratory, giving the AD2C platform a modular architecture that the company intends to apply beyond HCC.
The question Phase 1 will actually answer is whether two payloads on one antibody can be dosed safely at exposures that matter. Dual-payload ADCs carry a more complex tolerability profile than single-payload constructs, and the dose-limiting toxicity data from the escalation phase will determine whether the mechanistic rationale translates into a workable therapeutic window. Watch the DLT readout from the initial cohorts.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
